Past year
All results
- All results
- Verbatim
Mar 15, 2024 · In the current era, DLI is most commonly given at a starting dose of 1 x 107 cells/kg with an interval of approximately four weeks between infusions to allow ...
Dec 18, 2023 · Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia ...
Nov 1, 2023 · Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002;. 100(2):397-405. 9. Fozza C ...
Oct 12, 2023 · Donor lymphocyte infusion (DLI) is used to induce remission in patients who relapse after allogeneic stem cell transplantation (allo-HSCT).
Missing: initial | Show results with:initial
Apr 11, 2024 · Donor lymphocyte infusions (DLIs) are an established cellular strategy for preventing AML relapse following allo-SCT, and are commonly administered ...
May 15, 2024 · lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia.
Mar 25, 2024 · Allogeneic hematopoietic stem cell transplantation (allo-SCT) is recognized as the most potent anti-leukemic treatment for patients with acute myeloid leukemia ...
Missing: initial | Show results with:initial
Jun 11, 2024 · In this review, we discuss the therapeutic landscape of relapsed pediatric AML, including conventional chemotherapy, targeted therapies, and the challenges of ...
Missing: administering | Show results with:administering
Apr 4, 2024 · The optimal DLI (CD3) T-cell dose has not been firmly established and clinical practice is largely guided by empirical data and institutional experience.
Missing: administering | Show results with:administering
Sep 24, 2024 · The dose will be increased to 5 × 107 expanded cells/kg and 1 × 108 expanded cells/kg in successive escalations based on no significant infusional toxicity or ...
Missing: myelogenous | Show results with:myelogenous